View
10
Download
2
Category
Preview:
Citation preview
1
WHO guidelines for maternal and newborn health
Antenatal Care (2016)Improving preterm birth outcomes (2015)
Postnatal care (2014)
Reproductive Health and Research (RHR)Maternal, Newborn, Child and Adolescent Health (MCA)
26 September 2017
Towards access, quality and coverage of health services
Critical time for global health
• MDGs to SDGs• Two complementary strategies with
shared objectives– Every Newborn Action Plan (ENAP) – Ending Preventable Maternal Mortality (EPMM)
• New Global Strategy for women's children's and adolescent's health– Survive, thrive, transform
• Launch of GFF as a financing platform for SRMNCAH
Coverage and quality matter
• Due to focused efforts, facility-based birthsare increasing globally
– Higher proportions of avoidable maternal and perinatal morbidity and mortality occur in facilities
• Major roadblock: Quality of care
The lives of nearly 3 million babies and women could be saved each year with high coverage of quality care around birth and care for small and sick babies
55
Quality of care throughout the continuum
Ø Reducing mortality and morbidity
Ø Providing respectful care that takes into account clients’ values and preferences
Ø Optimizing service delivery within health systems
WHO envisions a world where “every pregnant woman and newborn receives quality care throughout the pregnancy, childbirth and the postnatal period”.
Positive pregnancy experienceü A healthy pregnancy for mother and
baby (including preventing or treating risks, illness and death)
ü Physical and sociocultural normality during pregnancy
ü Effective transition to positive labour and birth
ü Positive motherhood (including maternal self-esteem, competence and autonomy)
Prioritizes person-centred health and well-being:
66
What is a WHO guideline?
q “A WHO guideline is any document, whatever its title, that contains WHO recommendations about health interventions, whether they be clinical, public health or policy interventions.”
q ”A recommendation provides information about what policy-makers, health-care providers or patients should do. It implies a choice between different interventions that have an impact on health and that have ramifications for the use of resources.”
77
WHO Antenatal CareGuidelines (2016)
88
Antenatal Care (ANC) is critical
Through timely and appropriate, evidence-based actions related to health promotion, disease
prevention, screening, and treatment
q Reduces complications from pregnancy and childbirth
q Reduces stillbirths and newborn deaths
q Integrated care delivery throughout pregnancy
99
ANC model – positive pregnancy experience
Overarching aim
To provide pregnant women with respectful, individualized, person-centred care at every contact, with implementation of effective clinical practices (interventions and tests), and provision of relevant
and timely information, and psychosocial and emotional support, by practitioners with good
clinical and interpersonal skills within a well functioning health system.
1010
Most recent recommendations on routine ANC
A. Nutritional interventions (14)B. Maternal and fetal assessment (8)C. Preventive measures (5)D. Interventions for common physiological
symptoms (6)E. Health system interventions to improve
the utilization and quality of ANC (6)
Grouped under five areas: 49 recommendations
Routine ANC recommendations from other WHO guidelines (10)
1111
WHO ANC model 2016 1
1212
Contact versus visits
q The guideline uses the term ‘contact’ - it implies an active connection between a pregnant woman and a health care provider that is not implicit with the word ‘visit’.
q In terms of the operationalization of this recommendation, ‘contact’ can take place at the facility or at community level– be adapted to local context through community outreach and lay health
worker programmes– Midwife-led continuity-of-care models, in which a known midwife or
small group of known midwives supports a woman throughout the antenatal, intrapartum and postnatal continuum, are recommended for pregnant women in settings with well functioning midwifery programmes.
q Context-specific recommendations– Interventions (such as malaria, tuberculosis)– Health system (such as task shifting)
2
1313
Early ultrasound
q In the new WHO ANC guideline, an ultrasound scan before 24 weeks’ gestation is recommended for all pregnant women to:v estimate gestational agev detect fetal anomalies and multiple pregnanciesv and enhance the maternal pregnancy experience
q An ultrasound scan after 24 weeks’ gestation (late ultrasound) is not recommended for pregnant women who have had an early ultrasound scan. – Stakeholders should consider offering a late ultrasound scan to pregnant women
who have not had an early ultrasound scan.
q The implementation and impact of this recommendation on health outcomes, facility utilization, and equity should be monitored at the health service, regional, and country level– based on clearly defined criteria and indicators associated with locally agreed and
appropriate targets.
3
1414
Effective implementation of ANC requires:
q Health systems approach and strengthening o Continuity of careo Integrated service delivery o Improved communication with, and support for womeno Availability of supplies and commoditieso Empowered health care providers
§ Recruitment and retention of staff in rural and remoteareas
§ Capacity building
4
1515
WHO recommendations on interventions to
improve preterm birth outcomes
(2015)
1616
Guideline scope – population and interventions
• Population– pregnant women at imminent risk of preterm birth (<37 weeks
gestation) and preterm babies immediately after birth in all settings• Interventions
– Antenatal corticosteroids– Tocolytics– Magnesium sulfate for fetal neuroprotection– Antibiotics for PTL with intact/ruptured membranes– Optimal mode of birth– Thermal care (Kangaroo Mother Care (KMC), plastic wraps)– Continuous Positive Airway Pressure (CPAP)– Surfactant– Oxygen therapy
Filename
Maternal
Newborn
1717
Guideline scope – critical outcomesMaternal
• Birth prior to 28, 32, 34 or 37 weeks of gestation
• Pregnancy prolongation (interval between randomization into the study and birth, < 48 hours or < 7 days)
• Severe maternal morbidity or death
• Maternal sepsis (chorioamnionitis, puerperal sepsis)
• Severe adverse effects of treatment
Newborn• Neonatal death• Fetal death or stillbirth• Perinatal death (fetal or early
neonatal death)• Severe neonatal morbidity • Birth weight (mean; low or very
low)• Infant or child death• Long-term morbidity
Filename
1818
Antenatal corticosteroids (ACS) for preterm birth (PTB)
• ACS therapy is recommended for women at risk of preterm birth from 24 weeks to 34 weeks of gestation when the following conditions are met:
– Gestational Age (GA)assessment can be accurately undertaken;– preterm birth is considered imminent;– there is no clinical evidence of maternal infection;– adequate childbirth care is available (including the capacity to recognize and
safely manage preterm labour and birth);– the preterm newborn can receive adequate care if needed (including
resuscitation, thermal care, feeding support, infection treatment and safe oxygen use).
Strong recommendation based on moderate-quality evidence for newborn outcomes and low-quality evidence for maternal outcomes
1
1919
ACS for preterm birth (2)q Recommended for women:
– pre-term birth (PTB) is imminent within 7 days of starting treatment, including first 24 hours.
– Single or multiple birth– Preterm premature rupture of membranes (PPROM) and no clinical
signs of infection– Hypertensive disorders in pregnancy– Women with growth restricted fetus– women with pre-gestational and gestational diabetes (accompanied
by interventions to optimize maternal blood glucose control)
q Not recommended for women:– women with chorioamnionitis who are likely to deliver preterm– women undergoing planned caesarean section at late preterm
gestations (34–36+6 weeks)
o Intramuscular (IM) dexamethasone or betamethasone (total 24 mg)
1
2020
Tocolytics for preterm birth
• Tocolytic treatments (acute and maintenance treatments) are not recommended for women at risk of imminent preterm birth for the purpose of improving newborn outcomes. (Conditional recommendation, very low quality-evidence)
– Acute use to delay birth (up to 48 hours) can be considered for in-utero fetal transfer to appropriate neonatal care setting
– Nifedipine is the preferred agent in such context
– Betamimetics have a higher risk of adverse drug reactions and should not be used
– Further trials needed on whether tocolytics can actually improve substantive perinatal outcomes are a research priority
2
2121
Magnesium sulfate for neuroprotection
• Magnesium sulfate is recommended for women at risk of imminent preterm birth before 32 weeks of gestation for prevention of cerebral palsy in the infant and child. (Strong recommendation, moderate quality-evidence)
– Should only be given if preterm birth is likely within the next 24 hours
– Insufficient evidence to recommend one dosing regimen over the other. Tested regimens include:
• IV 4 g, then 1 g/hour until delivery or for 24 hours, whichever came first;
• IV 4 g over 30 minutes or IV 4 g bolus as single dose;
• IV 6 g over 20-30 minutes, followed by IV maintenance of 2 g/hour.
3
2222
Antibiotics for women with PPROM
• Antibiotic administration is recommended for women with PPROM
- No antibiotic without confirming the diagnosis of PPROM.
– Monitor women for signs of clinical chorioamnionitis
• Erythromycin is recommended as the antibiotic of choice for prophylaxis in women with PPROM (Conditional recommendation, moderate quality-evidence)
– Oral erythromycin 250 mg four times a day for 10 days (or until delivery)
q Combination of amoxicillin and clavulanic acid (“co-amoxiclav”) is not recommended
4
2323
Kangaroo Mother Care (KMC)
§ Kangaroo mother care is recommended for the routine care of newborns weighing 2000 g or less at birth, and should be initiated in healthcare facilities as soon as the newborns are clinically stable.
§ As close to continuous KMC as possible
§ Intermittent Kangaroo mother care if continuous KMC is not possible
5
2424
Respiratory support: CPAP, Surfactant, Oxygen
§ Continuous positive airway pressure (CPAP) therapy is recommended for the treatment of preterm newborns with respiratory distress syndrome and should be started as soon as the diagnosis is made.
§ Surfactant replacement therapy is recommended for intubated and ventilated newborns with respiratory distress syndrome.
§ During ventilation of preterm babies born at or before 32 weeks of gestation, it is recommended to start oxygen therapy with 30% oxygen or air (if blended oxygen is not available), rather than with 100% oxygen.
6
2525
Caution: respiratory support6
2626
WHO guidelines onpostnatal care of
the mother and the newborn (2013)
2727
Routine postnatal care: content
q Monitoring and assessment of maternal and neonatal well-being
q Support for good caregiving practices – Warmth, hygiene, early initiation and exclusive
breastfeeding, responsive care and stimulationq Prevention, detection and treatment of complications– Maternal: postpartum hemorrhage (PPH), hypertension,
infection– Neonatal: asphyxia, prematurity, sepsis
§Providing information and counselling― Nutrition, family planning, psychological support
2828
Twelve recommendations
q Assessment of the babyq Exclusive breastfeedingq Cord care q Other postnatal care for the
newborn
q Assessment of the motherq Counsellingq Iron and folic acid
supplementationq Prophylactic antibioticsq Psychological support
§ Timing of discharge from a health facility§ Number and timing of postnatal contacts§ Home visits for postnatal care
2929
Timing of discharge and follow up care
q After an uncomplicated vaginal birth in a health facility, healthy mothers and newborns should receive care in the facilities for at least 24 h after birth– For the newborn, this includes an immediate assessment at birth, a full clinical
examination around 1 h after birth and before discharge
– If birth is at home, the first postnatal contact should be as early as possible within 24 h of birth
q At least three additional postnatal contacts are recommended for all mothers and newborns, on day 3 (48-72 h), between days 7-14 after birth, and 6 weeks after birth
Filename
3030
Timing of discharge and follow up care
q Home visits are recommended for care of the mother and newborn
in the first week after birth
– By midwives, other skilled providers , or well-trained and supervised
community health workers (CHWs)
q Clean, dry cord care is recommended for newborns born in health
facilities, and at home in low neonatal mortality settings
q Daily chlorhexidine application to the umbilical cord stump during
the first week of life is recommended for newborns who are born at home in settings with high neonatal mortality (> 30 neonatal
deaths per 1000 live births)
q Bathing should be delayed to after 24 hours of birth.
Filename
3131
From guidelines to policies and practiceTowards access, quality and coverage of health services
3232 Filename
3333
Programme implications of new WHO guidelines
q Review and update national policies and guidelinesq Review and update national standards and practice tools for
improving quality of careq Facilitate a continuum between facility- and home-based care q Ensure adequate infrastructureq Ensure adequate human resources with relevant skills mix q Update advocacy and communication materialsq Monitor adherence to recommendations
34
WHO conceptual framework for QoC
3535
Quality of care implementation framework
Develop an operational plan and assign responsibility
Establish national policy, strategy and structures
Adapt and adopt quality of care standards
Build capability for quality improvement interventions
Agree indicators and monitoring framework
Build a broad coalition of stakeholders Conduct a landscape analysis and review data from health facilities
Plan
Study
DoAct Implement interventions
Monitor progress and Learn
Refine or adapt interventions
3636
Tout mettre en commun
Refine or adapt intervention
3737
HOW to strengthen the quality of the provision of care in EmONC facilities?
37
Data Analysis
Response for improving
quality
Data Collection
(key RH and MNH indicators on
quarterly basis)
Advocacy
PHASE 1
Design
Prioritisation and EmONC mapping
Regular review of the performance of the MNH monitoring and qualityimprovement system
Situation Analysis(Baseline Information)
§ National HealthPlan, RMNCAH plans/strategies
§ EmONC NeedAssessments(including ‘rapid’ NeedAssessments)
§ HMIS§ Surveys: DHS,
SARA, etc
PHASE 2
PHASE 3
PHASE 4
PHASE 5
PHASE 6
PLANNING of national network of EmONC facilities
MONITORING and QUALITY IMPROVEMENT (PDSA)
Addressing the ‘planning issues’ Addressing the ‘implementation issue’
GIS/AccessMod
GIS/AccessMod
Contact for further information on the approach: UNFPA Technical Division (Michel Brun brun@unfpa.org and Jean-Pierre Monet monet@unfpa.org)
3838
Results from the implementation of the approach in Togo (since 2013)
38
Ø Missions and staffing of a BEMONC facilities defined (national BEmONC standard)
Ø 65 additional midwives deployed in BEmONC facilities
Ø Regular monitoring of key RH and MNH indicators (DHIS2) and ‘PDSA’ cycle at facility and sub-national levels
Proportion of EmONC facilities with Magnesium Sulfate
2014 2016
0%
88%
Proportion of EmONC facilities with intrauterine device (IUD)
2014 2016
0%
51%
Proportion of EmONC facilities with vacuum extractions
performed
2014 2016
0%-5%
47%
29
15
15
17
Q1 2013 Q1 2015
Number of functioning EmONC facilities in Togo (24h/7d)
CEmONC BEmONC
Q1 2016
3939
Lessons learned from the implementation of the approach in Haiti, Togo, Madagascar, Guinea, Burundi and Benin
39
q EmONC facility network – phased approach starting with limited number of facilities (in line with the international recommended standard) while maximizing the population coverage (eg. using GIS/AccessMod)
q Monitoring of a limited amount of data (one page of data) to be defined by providers and stakeholders in a national workshop (indicators)
q Pro active and supportive collection, analyzis of data in facilities (‘support teams’ at subnational levels) and implementation of responses
q Quality Improvement process and concepts of Implementation science (‘bottom-up approach’, empowerment of facility staff’, right to fail, mentorship program, etc) leveraged to improve quality of care and organization of services
q Close monitoring of the program (in particular the quality improvement)
q Importance of national coordination mechanisms in SRMNCAH (eg. H6) for national scope of the process.
4040
Appendix
40
4141
EmONC Signal Functions – 24h/7d
41
1. Administer parenteral antibiotics2. Administer uterotonic drugs3. Administer parenteral
anticonvulsants4. Manually remove the placenta5. Remove retained products6. Perform assisted vaginal delivery 7. Perform basic neonatal
resuscitation (with bag and mask)8. Blood transfusion9. Cesarean delivery
Basic EmONC
ComprehensiveEmONC
4242
Global Guidance on EmONC Indicators
42
q 5 EmONC facilities per 500,000 population (minimum recommendation)
q At least one of these provides C-EmONC level care; others might be B-EmONCs or additional C-EmONCs
q Functioning EmONCdefined by functioning 24h/7d and performing all signal functions in the last 3 months
http://www.who.int/reproductivehealth/publications/monitoring/9789241547734/en/
4343
Situation Analysis: EmONC availability in high burden countries
43
# functioning EmONCfacilities with QoC
# of
Em
ON
Cfa
cilit
ies
Planning Issues Implementation Issues
# of Recommended EmONC facilities
# of Planned EmONC facilities
by the MoH
# of Functioning EmONC facilities
Source: Averting Maternal Death and Disability (AMDD), Columbia University, New York (based on EmONC Needs Assessments of 15 countries)
International Standard
(5 EmONC per 500,000 pop.)
30%
100%
4444
Details on prioritization of EmONC facilities (Phase 3)
44
Geographic accessibility analysis – Example of Togo (2015)
BEmONC facilities
4545
Details on prioritization of EmONC facilities (Phase 3)
45
Coverage of population at 120min (catchment areas of facilities) – Example of Burundi (2017)
4646
National EmONC ‘monitoring sheet’ (one pager)
46
EmONC Signal Functions*MNH service availability (includingKMC, PMTCT, BCG/Polio vaccination for newborn, # newborns with post-natal visit)
HR* (midwives), Supplies*, infrastr., FP
Direct Obstetric Complications* (# patients managed/referred, # of deaths, # of deaths notified, # of deathsreviewed) and indirect complications
Neonatal complications* (# patients managed/referred, # of deaths, # of deaths notified, # of deaths reviewed)
HIS/
Recommended